enGene Holdings Inc. (NASDAQ:ENGN - Free Report) - Research analysts at Leerink Partnrs boosted their FY2024 earnings estimates for shares of enGene in a research report issued on Wednesday, October 30th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will earn ($1.42) per share for the year, up from their previous forecast of ($1.48). The consensus estimate for enGene's current full-year earnings is ($1.56) per share. Leerink Partnrs also issued estimates for enGene's Q4 2024 earnings at ($0.32) EPS, FY2025 earnings at ($1.43) EPS, FY2026 earnings at ($2.55) EPS, FY2027 earnings at ($1.82) EPS and FY2028 earnings at ($0.64) EPS.
enGene (NASDAQ:ENGN - Get Free Report) last released its quarterly earnings results on Tuesday, September 10th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.05.
A number of other brokerages have also issued reports on ENGN. Morgan Stanley restated an "overweight" rating and set a $40.00 target price on shares of enGene in a research report on Wednesday, September 11th. Oppenheimer restated an "outperform" rating and set a $30.00 target price on shares of enGene in a research report on Tuesday, September 24th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, enGene has an average rating of "Buy" and an average target price of $33.67.
Read Our Latest Analysis on ENGN
enGene Stock Performance
Shares of NASDAQ:ENGN traded up $0.04 on Friday, reaching $8.89. 58,531 shares of the company's stock were exchanged, compared to its average volume of 112,370. The company has a fifty day moving average of $7.28 and a 200-day moving average of $9.33. enGene has a twelve month low of $4.42 and a twelve month high of $27.99. The company has a debt-to-equity ratio of 0.09, a quick ratio of 19.52 and a current ratio of 19.52.
Hedge Funds Weigh In On enGene
Several large investors have recently modified their holdings of the business. Logos Global Management LP raised its stake in shares of enGene by 50.0% during the second quarter. Logos Global Management LP now owns 1,200,000 shares of the company's stock valued at $11,316,000 after acquiring an additional 400,000 shares during the last quarter. SR One Capital Management LP bought a new position in shares of enGene during the second quarter valued at $4,715,000. Janus Henderson Group PLC bought a new position in shares of enGene during the first quarter valued at $17,095,000. Finally, Altitude Crest Partners Inc. bought a new position in enGene during the first quarter worth $2,039,000. Institutional investors own 64.16% of the company's stock.
Insider Buying and Selling
In related news, CEO Ronald Harold Wilfred Cooper acquired 10,000 shares of the company's stock in a transaction that occurred on Friday, September 27th. The stock was acquired at an average price of $5.70 per share, with a total value of $57,000.00. Following the purchase, the chief executive officer now directly owns 10,000 shares in the company, valued at approximately $57,000. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, CEO Ronald Harold Wilfred Cooper acquired 10,000 shares of the company's stock in a transaction that occurred on Friday, September 27th. The stock was acquired at an average price of $5.70 per share, with a total value of $57,000.00. Following the purchase, the chief executive officer now directly owns 10,000 shares in the company, valued at approximately $57,000. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Growth Opportunities F. Forbion acquired 341,332 shares of the company's stock in a transaction that occurred on Monday, September 30th. The stock was bought at an average cost of $6.34 per share, with a total value of $2,164,044.88. Following the purchase, the insider now owns 2,400,791 shares in the company, valued at $15,221,014.94. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 420,965 shares of company stock worth $2,651,103. Corporate insiders own 13.70% of the company's stock.
About enGene
(
Get Free Report)
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
See Also
Before you consider enGene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and enGene wasn't on the list.
While enGene currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
